whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial
Malleable protein matrix (MPM) is a unique whey-derived ingredient obtained through a fermentation process using proprietary lactic acid bacteria strains from the Lactobacillus kefiranofaciens species. Because evidence from animal models suggests that MPM decreases serum lipid concentrations, the pu...
Gespeichert in:
Veröffentlicht in: | Journal of dairy science 2011-02, Vol.94 (2), p.589-601 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 601 |
---|---|
container_issue | 2 |
container_start_page | 589 |
container_title | Journal of dairy science |
container_volume | 94 |
creator | Berthold, H.K Schulte, D.M Lapointe, J.F Lemieux, P Krone, W Gouni-Berthold, I |
description | Malleable protein matrix (MPM) is a unique whey-derived ingredient obtained through a fermentation process using proprietary lactic acid bacteria strains from the Lactobacillus kefiranofaciens species. Because evidence from animal models suggests that MPM decreases serum lipid concentrations, the purpose of the present trial was to assess the hypothesis that MPM exerts lipid-lowering effects in humans. A total of 161 subjects (50% male; age 54.5 ± 9.8 yr, body mass index 26.3 ± 3.6 kg/m2) with hypercholesterolemia with baseline low-density lipoprotein cholesterol (LDL-C) levels of 181 ± 30 mg/dL and normal triglyceride (TG) levels (131 ± 55 mg/dL) were randomized to receive MPM (2 × 15 g/d) or matching placebo. A 6-wk run-in phase was followed by a double-blind 12-wk treatment phase after randomization. The data were analyzed on an intention-to-treat basis. The primary outcome measure was the percentage change of LDL-C. The secondary outcome measures were changes in TG and high-density lipoprotein cholesterol concentrations as well as changes in other cardiovascular risk factors. After 12 wk of treatment, the relative TG decrease from baseline reached 9.8%, whereas LDL-C was slightly decreased (by 1.5%) following MPM treatment compared with placebo in the intention-to-treat cohort. The treatment effect on TG reduction was much higher in the subset of subjects having TG levels at baseline of 150 mg/dL or above (n = 42), reaching 20.0% compared with placebo. High-density lipoprotein cholesterol concentrations, blood pressure, and fasting blood glucose remained unchanged, whereas a positive treatment effect was seen on hemoglobin A1c. The MPM product was tolerated well without severe adverse events. In conclusion, MPM has significant TG-lowering properties in subjects with combined hypercholesterolemia and higher TG levels. Its effects on LDL-C concentrations and glucose metabolism deserve further investigation. |
doi_str_mv | 10.3168/jds.2010-3115 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_847282862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>847282862</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-6ee84229eca22e3ceaf63acc1bfd0b2784dacf6dec87758081149feeb7a737863</originalsourceid><addsrcrecordid>eNpFkU1v1DAQhi0EotvCkSv4gjil-CMfDreqgoJUiQP0HE2cSdcrJ15sR-3yf_ifTNgFTuN59eidGb-MvZLiUsvavN8N6VIJKQotZfWEbWSlKnq35inbCKFUIbRQZ-w8pR21UonqOTujWjVCmQ379bDFAx8xTjhnyC7MfB_DsNjMJ_Aeofe4KhndTEqO7pEPaCNCwsSpvfcHi9ENyG2YLZnEPy6JE5-Wfoc2J_7g8pZvD3uMdhs8poyRyuTgA7_iEeYhTO4nDnzvwWIfCrLKRHiSaAT4F-zZCD7hy1O9YHefPn6__lzcfr35cn11W1htqlzUiKZUqkULSqG2CGOtwVrZj4PoVWPKAexY0_6maSojjJRlOyL2DTS6MbW-YO-OvnTxj4X27CaXLHoPM4YldaZslFGmVkQWR9LGkFLEsdtHN0E8dFJ0azAdBdOtwXRrMMS_Pjkv_YTDP_pvEgS8PQGQLPiRfsW69J_TNLcVq9GbIzdC6OA-EnP3jeaUQoi2rKXWvwE3L6Xx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>847282862</pqid></control><display><type>article</type><title>whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Berthold, H.K ; Schulte, D.M ; Lapointe, J.F ; Lemieux, P ; Krone, W ; Gouni-Berthold, I</creator><creatorcontrib>Berthold, H.K ; Schulte, D.M ; Lapointe, J.F ; Lemieux, P ; Krone, W ; Gouni-Berthold, I</creatorcontrib><description>Malleable protein matrix (MPM) is a unique whey-derived ingredient obtained through a fermentation process using proprietary lactic acid bacteria strains from the Lactobacillus kefiranofaciens species. Because evidence from animal models suggests that MPM decreases serum lipid concentrations, the purpose of the present trial was to assess the hypothesis that MPM exerts lipid-lowering effects in humans. A total of 161 subjects (50% male; age 54.5 ± 9.8 yr, body mass index 26.3 ± 3.6 kg/m2) with hypercholesterolemia with baseline low-density lipoprotein cholesterol (LDL-C) levels of 181 ± 30 mg/dL and normal triglyceride (TG) levels (131 ± 55 mg/dL) were randomized to receive MPM (2 × 15 g/d) or matching placebo. A 6-wk run-in phase was followed by a double-blind 12-wk treatment phase after randomization. The data were analyzed on an intention-to-treat basis. The primary outcome measure was the percentage change of LDL-C. The secondary outcome measures were changes in TG and high-density lipoprotein cholesterol concentrations as well as changes in other cardiovascular risk factors. After 12 wk of treatment, the relative TG decrease from baseline reached 9.8%, whereas LDL-C was slightly decreased (by 1.5%) following MPM treatment compared with placebo in the intention-to-treat cohort. The treatment effect on TG reduction was much higher in the subset of subjects having TG levels at baseline of 150 mg/dL or above (n = 42), reaching 20.0% compared with placebo. High-density lipoprotein cholesterol concentrations, blood pressure, and fasting blood glucose remained unchanged, whereas a positive treatment effect was seen on hemoglobin A1c. The MPM product was tolerated well without severe adverse events. In conclusion, MPM has significant TG-lowering properties in subjects with combined hypercholesterolemia and higher TG levels. Its effects on LDL-C concentrations and glucose metabolism deserve further investigation.</description><identifier>ISSN: 0022-0302</identifier><identifier>EISSN: 1525-3198</identifier><identifier>DOI: 10.3168/jds.2010-3115</identifier><identifier>PMID: 21257028</identifier><identifier>CODEN: JDSCAE</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>animal models ; Animal productions ; Anticholesteremic Agents - therapeutic use ; Biological and medical sciences ; blood glucose ; blood lipids ; blood pressure ; body mass index ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Cultured Milk Products ; Double-Blind Method ; Female ; fermentation ; Food industries ; Fundamental and applied biological sciences. Psychology ; glycohemoglobin ; high density lipoprotein cholesterol ; Humans ; hypercholesterolemia ; Hypercholesterolemia - blood ; Hypercholesterolemia - drug therapy ; lactic acid bacteria ; lipid content ; low density lipoprotein ; Male ; Middle Aged ; Milk and cheese industries. Ice creams ; Milk Proteins - therapeutic use ; Risk Factors ; Terrestrial animal productions ; Treatment Outcome ; Triglycerides - blood ; Vertebrates ; whey ; Whey Proteins</subject><ispartof>Journal of dairy science, 2011-02, Vol.94 (2), p.589-601</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 American Dairy Science Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-6ee84229eca22e3ceaf63acc1bfd0b2784dacf6dec87758081149feeb7a737863</citedby><cites>FETCH-LOGICAL-c385t-6ee84229eca22e3ceaf63acc1bfd0b2784dacf6dec87758081149feeb7a737863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23828905$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21257028$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berthold, H.K</creatorcontrib><creatorcontrib>Schulte, D.M</creatorcontrib><creatorcontrib>Lapointe, J.F</creatorcontrib><creatorcontrib>Lemieux, P</creatorcontrib><creatorcontrib>Krone, W</creatorcontrib><creatorcontrib>Gouni-Berthold, I</creatorcontrib><title>whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial</title><title>Journal of dairy science</title><addtitle>J Dairy Sci</addtitle><description>Malleable protein matrix (MPM) is a unique whey-derived ingredient obtained through a fermentation process using proprietary lactic acid bacteria strains from the Lactobacillus kefiranofaciens species. Because evidence from animal models suggests that MPM decreases serum lipid concentrations, the purpose of the present trial was to assess the hypothesis that MPM exerts lipid-lowering effects in humans. A total of 161 subjects (50% male; age 54.5 ± 9.8 yr, body mass index 26.3 ± 3.6 kg/m2) with hypercholesterolemia with baseline low-density lipoprotein cholesterol (LDL-C) levels of 181 ± 30 mg/dL and normal triglyceride (TG) levels (131 ± 55 mg/dL) were randomized to receive MPM (2 × 15 g/d) or matching placebo. A 6-wk run-in phase was followed by a double-blind 12-wk treatment phase after randomization. The data were analyzed on an intention-to-treat basis. The primary outcome measure was the percentage change of LDL-C. The secondary outcome measures were changes in TG and high-density lipoprotein cholesterol concentrations as well as changes in other cardiovascular risk factors. After 12 wk of treatment, the relative TG decrease from baseline reached 9.8%, whereas LDL-C was slightly decreased (by 1.5%) following MPM treatment compared with placebo in the intention-to-treat cohort. The treatment effect on TG reduction was much higher in the subset of subjects having TG levels at baseline of 150 mg/dL or above (n = 42), reaching 20.0% compared with placebo. High-density lipoprotein cholesterol concentrations, blood pressure, and fasting blood glucose remained unchanged, whereas a positive treatment effect was seen on hemoglobin A1c. The MPM product was tolerated well without severe adverse events. In conclusion, MPM has significant TG-lowering properties in subjects with combined hypercholesterolemia and higher TG levels. Its effects on LDL-C concentrations and glucose metabolism deserve further investigation.</description><subject>animal models</subject><subject>Animal productions</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>blood glucose</subject><subject>blood lipids</subject><subject>blood pressure</subject><subject>body mass index</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Cultured Milk Products</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>fermentation</subject><subject>Food industries</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>glycohemoglobin</subject><subject>high density lipoprotein cholesterol</subject><subject>Humans</subject><subject>hypercholesterolemia</subject><subject>Hypercholesterolemia - blood</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>lactic acid bacteria</subject><subject>lipid content</subject><subject>low density lipoprotein</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Milk and cheese industries. Ice creams</subject><subject>Milk Proteins - therapeutic use</subject><subject>Risk Factors</subject><subject>Terrestrial animal productions</subject><subject>Treatment Outcome</subject><subject>Triglycerides - blood</subject><subject>Vertebrates</subject><subject>whey</subject><subject>Whey Proteins</subject><issn>0022-0302</issn><issn>1525-3198</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU1v1DAQhi0EotvCkSv4gjil-CMfDreqgoJUiQP0HE2cSdcrJ15sR-3yf_ifTNgFTuN59eidGb-MvZLiUsvavN8N6VIJKQotZfWEbWSlKnq35inbCKFUIbRQZ-w8pR21UonqOTujWjVCmQ379bDFAx8xTjhnyC7MfB_DsNjMJ_Aeofe4KhndTEqO7pEPaCNCwsSpvfcHi9ENyG2YLZnEPy6JE5-Wfoc2J_7g8pZvD3uMdhs8poyRyuTgA7_iEeYhTO4nDnzvwWIfCrLKRHiSaAT4F-zZCD7hy1O9YHefPn6__lzcfr35cn11W1htqlzUiKZUqkULSqG2CGOtwVrZj4PoVWPKAexY0_6maSojjJRlOyL2DTS6MbW-YO-OvnTxj4X27CaXLHoPM4YldaZslFGmVkQWR9LGkFLEsdtHN0E8dFJ0azAdBdOtwXRrMMS_Pjkv_YTDP_pvEgS8PQGQLPiRfsW69J_TNLcVq9GbIzdC6OA-EnP3jeaUQoi2rKXWvwE3L6Xx</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Berthold, H.K</creator><creator>Schulte, D.M</creator><creator>Lapointe, J.F</creator><creator>Lemieux, P</creator><creator>Krone, W</creator><creator>Gouni-Berthold, I</creator><general>Elsevier</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110201</creationdate><title>whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial</title><author>Berthold, H.K ; Schulte, D.M ; Lapointe, J.F ; Lemieux, P ; Krone, W ; Gouni-Berthold, I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-6ee84229eca22e3ceaf63acc1bfd0b2784dacf6dec87758081149feeb7a737863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>animal models</topic><topic>Animal productions</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>blood glucose</topic><topic>blood lipids</topic><topic>blood pressure</topic><topic>body mass index</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Cultured Milk Products</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>fermentation</topic><topic>Food industries</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>glycohemoglobin</topic><topic>high density lipoprotein cholesterol</topic><topic>Humans</topic><topic>hypercholesterolemia</topic><topic>Hypercholesterolemia - blood</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>lactic acid bacteria</topic><topic>lipid content</topic><topic>low density lipoprotein</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Milk and cheese industries. Ice creams</topic><topic>Milk Proteins - therapeutic use</topic><topic>Risk Factors</topic><topic>Terrestrial animal productions</topic><topic>Treatment Outcome</topic><topic>Triglycerides - blood</topic><topic>Vertebrates</topic><topic>whey</topic><topic>Whey Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berthold, H.K</creatorcontrib><creatorcontrib>Schulte, D.M</creatorcontrib><creatorcontrib>Lapointe, J.F</creatorcontrib><creatorcontrib>Lemieux, P</creatorcontrib><creatorcontrib>Krone, W</creatorcontrib><creatorcontrib>Gouni-Berthold, I</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of dairy science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berthold, H.K</au><au>Schulte, D.M</au><au>Lapointe, J.F</au><au>Lemieux, P</au><au>Krone, W</au><au>Gouni-Berthold, I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial</atitle><jtitle>Journal of dairy science</jtitle><addtitle>J Dairy Sci</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>94</volume><issue>2</issue><spage>589</spage><epage>601</epage><pages>589-601</pages><issn>0022-0302</issn><eissn>1525-3198</eissn><coden>JDSCAE</coden><abstract>Malleable protein matrix (MPM) is a unique whey-derived ingredient obtained through a fermentation process using proprietary lactic acid bacteria strains from the Lactobacillus kefiranofaciens species. Because evidence from animal models suggests that MPM decreases serum lipid concentrations, the purpose of the present trial was to assess the hypothesis that MPM exerts lipid-lowering effects in humans. A total of 161 subjects (50% male; age 54.5 ± 9.8 yr, body mass index 26.3 ± 3.6 kg/m2) with hypercholesterolemia with baseline low-density lipoprotein cholesterol (LDL-C) levels of 181 ± 30 mg/dL and normal triglyceride (TG) levels (131 ± 55 mg/dL) were randomized to receive MPM (2 × 15 g/d) or matching placebo. A 6-wk run-in phase was followed by a double-blind 12-wk treatment phase after randomization. The data were analyzed on an intention-to-treat basis. The primary outcome measure was the percentage change of LDL-C. The secondary outcome measures were changes in TG and high-density lipoprotein cholesterol concentrations as well as changes in other cardiovascular risk factors. After 12 wk of treatment, the relative TG decrease from baseline reached 9.8%, whereas LDL-C was slightly decreased (by 1.5%) following MPM treatment compared with placebo in the intention-to-treat cohort. The treatment effect on TG reduction was much higher in the subset of subjects having TG levels at baseline of 150 mg/dL or above (n = 42), reaching 20.0% compared with placebo. High-density lipoprotein cholesterol concentrations, blood pressure, and fasting blood glucose remained unchanged, whereas a positive treatment effect was seen on hemoglobin A1c. The MPM product was tolerated well without severe adverse events. In conclusion, MPM has significant TG-lowering properties in subjects with combined hypercholesterolemia and higher TG levels. Its effects on LDL-C concentrations and glucose metabolism deserve further investigation.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>21257028</pmid><doi>10.3168/jds.2010-3115</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-0302 |
ispartof | Journal of dairy science, 2011-02, Vol.94 (2), p.589-601 |
issn | 0022-0302 1525-3198 |
language | eng |
recordid | cdi_proquest_miscellaneous_847282862 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | animal models Animal productions Anticholesteremic Agents - therapeutic use Biological and medical sciences blood glucose blood lipids blood pressure body mass index Cholesterol, HDL - blood Cholesterol, LDL - blood Cultured Milk Products Double-Blind Method Female fermentation Food industries Fundamental and applied biological sciences. Psychology glycohemoglobin high density lipoprotein cholesterol Humans hypercholesterolemia Hypercholesterolemia - blood Hypercholesterolemia - drug therapy lactic acid bacteria lipid content low density lipoprotein Male Middle Aged Milk and cheese industries. Ice creams Milk Proteins - therapeutic use Risk Factors Terrestrial animal productions Treatment Outcome Triglycerides - blood Vertebrates whey Whey Proteins |
title | whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T04%3A03%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=whey%20fermentation%20product%20malleable%20protein%20matrix%20decreases%20triglyceride%20concentrations%20in%20subjects%20with%20hypercholesterolemia:%20A%20randomized%20placebo-controlled%20trial&rft.jtitle=Journal%20of%20dairy%20science&rft.au=Berthold,%20H.K&rft.date=2011-02-01&rft.volume=94&rft.issue=2&rft.spage=589&rft.epage=601&rft.pages=589-601&rft.issn=0022-0302&rft.eissn=1525-3198&rft.coden=JDSCAE&rft_id=info:doi/10.3168/jds.2010-3115&rft_dat=%3Cproquest_cross%3E847282862%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=847282862&rft_id=info:pmid/21257028&rfr_iscdi=true |